Login to Your Account

Clinic Roundup

Wednesday, December 15, 2010
Profectus Biosciences Inc., of Baltimore, said its Genevax IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I study with 48 healthy volunteers of an experimental DNA vaccine for HIV. The data were presented in Seattle at the annual HIV Vaccine Trials Network Conference held in November.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription